NEW YORK (GenomeWeb News) – Horizon Discovery today said that it has inked an agreement with SuperGen, under which it will provide screening services for the biopharmaceutical firm's drug candidates using its X-MAN technology.
The Cambridge, UK-based firm said that the deal covers the screening of lead compounds on a wide panel of human isogenic cell lines that comprise target genotypes of interest to SuperGen. The X-MAN technology may enable SuperGen to obtain information about the selectivity and mode-of-action of its compounds using model in vitro systems, said Horizon.
Under terms of the alliance, SuperGen will pay Horizon undisclosed fees. The partners expect to begin the collaboration this month.